Non-operative breast pathology: Apocrine lesions

Journal of Clinical Pathology

Volumn 60, Issue 12, 2007, Pages 1313-1320

  Wells, C A ^a   El Ayat, G A ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOCRINE CARCINOMA; APOCRINE GLAND; BREAST LESION; CARCINOMA IN SITU; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; REVIEW;

ADENOMA; APOCRINE GLANDS; BIOPSY; BREAST; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; FEMALE; FIBROCYSTIC BREAST DISEASE; HUMANS; HYPERPLASIA; METAPLASIA; NEOPLASM INVASIVENESS; PRECANCEROUS CONDITIONS;

EID: 37049029980     PISSN: 00219746     EISSN: None     Source Type: Journal    
DOI: 10.1136/jcp.2006.040626     Document Type: Review

References (62)

1. Bussolati G, Cattani M, Gugliotta P, et al. Morphologic and functional aspects of apocrine metaplasia in dysplastic and neoplastic breast tissue. Ann NY Acad Sci 1986;464:262-74.
2. Tavassoli F, Purcell C, Bratthauer G, et al. Androgen receptor expression along with loss of Bcl-2, ER, and PR expression in benign and malignant apocrine lesions of the breast: Implications of therapy. Breast J 1996;2:261-9.
3. Selim A, Wells C. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to estrogen and progesterone receptors. J Clin Pathol 1999;52:838- 41.
4. Mazoujian G, Haagensen D Jr. The immunopathology of gross cystic disease fluid proteins. Ann NY Acad Sci 1990;586:188-97.
5. Miller W, Scott W, Phil M, et al. Using biological measurements, can patients with benign breast disease who are at high risk of breast cancer be identified. Cancer Detect Prev 1992;16(Suppl):13- 20.
6. Devitt J. Clinical benign disorders of the breast and carcinoma of the breast. Surg Gynecol Obstet 1981;152:437-40.
7. Bruzzi P, Dogliotti L, Naldoni C, et al. Cohort study of association of risk of breast cancer with cyst type in women with gross cystic disease of the breast. BMJ 1997;314:925-8.
8. Dixon J, Lumsden A, Miller W. The relationship of cyst type to risk factors for breast cancer in patients with breast cystic disease. Eur J Cancer 1985;21:1047-50.
9. Dixon J, McDonald C, Miller W. Risk of breast cancer in women with palpable breast cysts: a prospective study. Lancet 1999;353:1742- 5.
10. Bundred NJ, West R, Dowd J, et al. Is there an increased risk of breast cancer in women who have had a breast cyst aspirated? Br J Cancer 1991;64:953-5.
11. Devitt J, To T, Miller A. Risk of breast cancer in women with breast cysts. Can Med Assoc J 1992;147:45-9.
12. Fitzgibbons P, Henson D, Hutter R. Benign breast changes and the risk of subsequent breast cancer: an update of the 1985 consensus statement. Cancer Committee of the College of American Pathologists. Arch Pathol Lab Med 1998;122:1053-5.
13. O'Malley F, Bane A. The spectrum of apocrine lesions of the breast. Adv Anat Pathol 2004;11:1-9.
14. Tsung J, Wang T, Wang S, et al. Cytological and biochemical studies of breast cyst fluid. Breast 2005;14:37-41.
15. Nielsen M, Thomsen J, Primdhal S, et al. Breast cancer atypia among young and middle aged women: a study of 110 medicolegal autopsies. Br J Cancer 1987;56:814-19.
16. Eusebi V, Damiani S, Losi L, et al. Apocrine differentiation of breast epithelium. Adv Anat Pathol 1997;4:139-55.
17. Wellings S, Alpers C. Apocrine cystic metaplasia: subgross pathology and prevalence in cancer-associated versus random autopsy breasts. Hum Pathol 1987;18:381-6.
18. Haagensen D. Is cystic disease related to breast cancer. Am J Surg Pathol 1991;15:687-94.
19. Dupont W, Page D. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146-51.
20. Page D, Dupont W, Jensen R. Papillary apocrine change of the breast: associations with atypical hyperplasia and risk of breast cancer. Cancer Epidemiol Biomarkers Prev 1996;5:29-32.
21. Hertel B, Zaloudek C, Kempson R. Breast adenomas. Cancer 1976;37:2891-905.
22. Eusebi V, Cassadei G, Bussolati G, et al. Adenomyoepithelioma of the breast with a distinct type of apocrine adenosis. Histopathology 1987;11:305-15.
23. Seidman J, Ashton M, Lefkowitz M. Atypical apocrine adenosis of the breast. A clinicopathologic study of 37 patients with 8.7 year follow up. Cancer 1996;77:2529-37.
24. Tavassoli F, Norris H. Intraductal apocrine carcinoma: a clinicopathologic study of 37 cases. Mod Pathol 1994;7:813-18.
25. Azzopardi J. Problems in breast pathology. Philadelphia, PA: WB Saunders, 1979:23-87.
26. Dupont W, Page D, Parl F, et al. Long-term risk of breast cancer in women with fibroadenoma. N Engl J Med 1994;331:10-15.
27. Scott M, Lagios M, Axelsson K, et al. Ductal carcinoma in situ of the breast reproducibility of histological subtype analysis. Hum Pathol 1997;28:967-73.
28. The Consensus Conference Committee. Consensus conference on the classification of ductal carcinoma in situ. Cancer 1997;80:1798- 802.
29. Leal C, Henrique R, Monteiro P, et al. Apocrine ductal carcinoma in situ of the breast: histologic classification and expression of biologic markers. Hum Pathol 2001;32:487-93.
30. NHS BSP. Guidelines for pathology reporting in breast disease. Publication 58, Version 2. Sheffield: NHS BSP, 2005.
31. Mossier J, Barton T, Brinkhous A, et al. Apocrine differentiation in human carcinoma. Cancer 1980;46:2463-71.
32. Rosen P. Rosen's breast pathology, 2nd edn., Philadelphia, PA: Lippincott W and Wilkins 2001.
33. Haagensen C. Diseases of the breast, 3rd edn., Philadelphia, PA: WB Saunders 1986.
34. Wick M, Lillemoe T, Copland G, et al. Gross cystic disease fluid protein 15 as a marker for breast cancer: immunohistochemical analysis of 690 human neoplasms and comparison with alpha lactalbumin. Hum Pathol 1989;20:281-7.
35. Papotti M, Eusebi V, Gugliotta P, et al. Immunohistochemical analysis of benign and malignant papillary lesions of the breast. Am J Surg Pathol 1983;7:451-61.
36. Eusebi V, Magalhaes F, Azzopardi J. Pleomorphic lobular carcinoma of the breast: an aggressive tumour showing apocrine differentiation. Hum Pathol 1992;23:655-62.
37. Pagani A, Eusebi V, Bussolati G. Detection of PIP-GCDFP15 gene expression in apocrine epithelium of the breast and salivary glands. Appl Immunohistochem 1994;2:29-35.
38. Ahmed A. Atlas of the ultrastructure of the human breast diseases. Edinburgh: Churchill Livingstone, 1978:41-5.
39. D'Amore E, Terrier-Lacombe M, Travagli J, et al. Invasive apocrine carcinoma of the breast. A long term follow-up study of 34 cases. Breast Cancer Res Treat 1988;12:37-44.
40. Abati A, Kimmel M, Rosen P. Apocrine mammary carcinomas. A clinicopathological study of 72 cases. Am J Clin Pathol 1990;94:371-7.
41. Frable W, Kay S. Carcinoma of the breast. Histologic and clinical features of apocrine tumours. Cancer 1968;21:756-63.
42. Schmitt F, Soares R, Seruca R. Bilateral apocrine carcinoma of the breast. Molecular and immunocytochemical evidence for two independent primary tumours. Virchows Arch 1998;433:505-9.
43. Gatalica Z. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ. Pathol Res Pract 1997;193:753-8.
44. Sapp M, Malik A, Hanna W. Hormone receptor profile of apocrine lesions of the breast. Breast J 2003;9:335-6.
45. Moinfar F, Okcu M, Tsybrovskyy O, et al. Androgen receptors frequently are expressed in breast carcinomas: potential relevance to new therapeutic strategies. Cancer 2003;98:703-11.
46. Japaze H, Emina J, Diaz C, et al. Pure invasive apocrine carcinoma of the breast: a new clinicopathological entity. Breast 2005;14:3-10.
47. European Working Group for Breast Screening Pathology (Chain Wells CA). European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn., Chapter 6a 2006 ISBN 92-79-01258-4.
48. Makunura CN, Curling OM, Yeomans P, et al. Apocrine adenosis within a radial scar: a case of false positive breast cytodiagnosis. Cylopathology 1994;5:123-8.
49. Selim AA, El-Ayat G, Wells CA. C-erbB2 oncoprotein expression, gene amplification and chromosome 17 aneusomy in apocrine adenosis of the breast: J Pathol 2000;191:138-42.
50. Selim AA, El-Ayat G, Wells CA. Expression of c-erbB2, p53, Bcl-2, Bax, c-myc and Ki-67 in apocrine metaplasia and apocrine change within sclerosing adenosis of the breast. Virchows Arch 2002;441:449-55.
51. Shim HS, Jung WH, Kim H, et al. Expression of androgen receptors and inhibin/activin alpha and betaA subunits in breast apocrine lesions. APMIS 2006;114:352-8.
52. Mazoujian G, Pinkus GS, Davis S, et al. Immunohistochemistry of a gross cystic disease fluid protein (GCDFP-15) of the breast. A marker of apocrine epithelium and breast carcinomas with apocrine features. Am J Pathol 1983;110:105-12.
53. Haagensen DE Jr, Dilley WG, Mazoujian G, et al. Review of GCDFP-15. An apocrine marker protein. Ann NY Acad Sci 1990;586:161-73.
54. Bundred NJ, Miller WR, Walker RA. An immunohistochemical study of the tissue distribution of the breast cyst fluid protein, zinc alpha 2 glycoprotein. Histopathology 1987;11:603-10.
55. Selim A, El-Ayat G, Wells C. Immunohistochemical localisation of gross cystic fluid protein 15,24 and 44 in ductal carcinoma in situ of the breast; relationship to the degree of differentiation. Histopathology 2001;39:198-202.
56. Celis JE, Gromova I, Gromov P, et al. Molecular pathology of breast apocrine carcinomas: a protein expression signature specific for benign apocrine metaplasia. FEBS Lett 2006;580:2935-44.
57. Tokes A, Kulka J, Paku S, et al. Claudin 1, 3 and 4 proteins and mRNA expression in benign and malignant breast lesions: a research study. Breast Cancer Res 2005;7:296-305.
58. Eusebi V, Millis R, Cattani M, et al. Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol 1986;123:532-41.
59. Selim A, El-Ayat G, Wells C. Androgen receptor expression in ductal carcinoma in situ of the breast: relation to estrogen and progesterone receptors. J Clin Pathol 2002;55:14-16.
60. Kasami M, Gobbi H, Dupont W, et al. Androgen receptor CAG repeat lengths in ductal carcinoma in situ of breast, longest in apocrine variety. Breast 2000;9:23-7.
61. Jones C, Damiani S, Wells D, et al. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast. Am J Pathol 2001;158:207-14.
62. Farmer P, Bonnefoi H, Becette V, et al. Identification of molecular apocrine breast tumours by microarray analysis. Oncogene 2005;24:4660-71.